203 Pb AR RMX

Drug Profile

203 Pb AR RMX

Alternative Names: 203 Pb-AR-RMX-15

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AREVA Med; RadioMedix
  • Developer Orano Med; RadioMedix
  • Class Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Neuroendocrine tumours

Most Recent Events

  • 22 Jun 2017 Efficacy data from a clinical trial in Neuroendocrine tumours (Diagnosis) released by RadioMedix and AREVA Med
  • 31 May 2017 Clinical trials in Neuroendocrine tumours (Diagnosis) (Parenteral) before May 2017
  • 31 May 2017 Areva Med and RadioMedix complete a clinical trial in Neuroendocrine tumours (Diagnosis) in May 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top